Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 2/20 | 0.66 |
| ▸ | ACLY | P53396 | 1/20 | 0.59 |
| ▸ | METAP2 | P50579 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2526708 | 0.89 | LMNA (0.66) | SERPINE1 | |
| SCHEMBL492024 | 0.82 | ACLY (0.81) | ACLYMETAP2 | |
| SCHEMBL420035 | 0.80 | SERPINE1 (1.00) | SERPINE1 | |
| SCHEMBL22452983 | 0.79 | MEN1 (0.48) | SERPINE1METAP2 | |
| SCHEMBL419525 | 0.79 | SERPINE1 (0.74) | SERPINE1 | |
| SCHEMBL1139356 | 0.78 | ACLY (0.78) | ACLYMETAP2 | |
| SCHEMBL419394 | 0.78 | SERPINE1 (0.72) | SERPINE1 | |
| SCHEMBL22452725 | 0.77 | MEN1 (0.46) | SERPINE1ACLY | |
| SCHEMBL9164473 | 0.77 | METAP2 (0.85) | ACLYMETAP2 | |
| Hydrochloric Acid SCHEMBL7409073 | 0.76 | METAP2 (0.82) | ACLYMETAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-11-06 | — | — | US | claimed |
| EP-1966131-A1 | INHIBITORS OF CCR9 ACTIVITY | Novartis Pharma AG (CH) | 2008-09-10 | — | — | EP | claimed |
| WO-2007071443-A1 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | claimed |
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-11-06 | — | — | US | disclosed |
| EP-1966131-A1 | INHIBITORS OF CCR9 ACTIVITY | Novartis Pharma AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071443-A1 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | CCR9, CCR1, CCR4 | SERPINE1 890/4885ACLY 3602/4885METAP2 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.